{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:04:04Z","timestamp":1785542644978,"version":"3.56.0"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,12,23]],"date-time":"2010-12-23T00:00:00Z","timestamp":1293062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The third generation bisphosphonate zoledronic acid has demonstrated efficacy in reducing skeletal\u2010related events in adult patients with multiple cancer types that have skeletal disease. The use of zoledronic acid in pediatric oncology patients with bone metastases for the purpose of reducing pain, improving bone strength and altering the progression of metastatic disease has not been thoroughly evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>From October 2005 to December 2008, 19 patients at the Aflac Cancer Center received one or more doses of zoledronic acid as part of their therapy. A retrospective review of these patients was performed and information was collected including indication for treatment, toxicities, and outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most patients (n\u2009=\u200915) received zoledronic acid following relapse of their malignancy with metastatic disease present in one or more bony sites. Hypocalcemia and hypophosphatemia were frequent, but did not result in clinical symptoms. More significant toxicities associated with zoledronic acid, including clinically apparent renal insufficiency and osteonecrosis of the jaw, were not seen. Overall, zoledronic acid was well tolerated in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The benefits of zoledronic acid seen in randomized trials of adults with bone metastases have sparked interest in its use for children with metastatic cancer. The administration of zoledronic acid in pediatric oncology appears safe, and may result in improved bone strength and pain control. Further evaluation is warranted to prospectively evaluate its efficacy and long\u2010term safety in pediatric patients with cancer and skeletal metastases. Pediatr Blood Cancer 2011;56:610\u2013614. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22681","type":"journal-article","created":{"date-parts":[[2010,12,23]],"date-time":"2010-12-23T18:18:13Z","timestamp":1293128293000},"page":"610-614","source":"Crossref","is-referenced-by-count":29,"title":["The use of zoledronic acid in pediatric cancer patients"],"prefix":"10.1002","volume":"56","author":[{"given":"Keith J.","family":"August","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wasilewski\u2010Masker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis B.","family":"Rapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,23]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2023H"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200501000-00002"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.105"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.09.004"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-1-52"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn240"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.06.003"},{"key":"e_1_2_5_12_2","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone\u2010stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier P","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035295"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-4096.2004.04831.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4508"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.05.009"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810013391402"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.4.610"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.86.5.356"},{"key":"e_1_2_5_20_2","first-page":"921","article-title":"Use of bisphosphonates in children and adolescents","volume":"15","author":"Allgrove J","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2003.00083.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199707000-00005"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-001-1098-7"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2009.22.8.763"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.06.066"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2009.22.1.55"},{"key":"e_1_2_5_27_2","article-title":"A phase I study of zoledronic acid and low\u2010dose cyclophosphamide in children with recurrent\/refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study","volume":"15","author":"Russell H","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_28_2","unstructured":"Children's Oncology Group.Zoledronic Acid and Combination Chemotherapy in Treating Patients with Newly Diagnosed Metastatic Osteosarcoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2010 March 2]. Available from: NLM Identifier: NCT00742924.http:\/\/clinicaltrials.gov\/show\/NCT00742924."},{"key":"e_1_2_5_29_2","unstructured":"Federation Nationale des Centres de Luttle Contre le Cancer.Combination Chemotherapy With or Without Zoledronic Acid in Treating Patients With Osteosarcoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2010 March 2]. Available from: NLM Identifier: NCT00470223.http:\/\/clinicaltrials.gov\/show\/NCT00470223."},{"key":"e_1_2_5_30_2","unstructured":"University Hospital Muenster.Study in Localized and Disseminated Ewing Sarcoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2010 March 2]. Available from: NLM Identifier: NCT00987636.http:\/\/clinicaltrials.gov\/show\/NCT00987636."},{"key":"e_1_2_5_31_2","first-page":"1551","article-title":"The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis","volume":"28","author":"Backman U","year":"2008","journal-title":"Anticancer Res"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.02.004"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200409000-00009"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0546"},{"key":"e_1_2_5_35_2","first-page":"285","article-title":"Zoledronate\u2010induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM\/Chk1\/cdc25 pathway in human osteosarcoma cells","volume":"31","author":"Iguchi T","year":"2007","journal-title":"Int J Oncol"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.20129"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21383"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj105"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.04.255"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0940-9"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.9579"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.10.1700"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc062792"},{"key":"e_1_2_5_44_2","unstructured":"Prescribing information.Zometa (zoledronic acid). 2009.http:\/\/www.pharma.us.novarits.com."},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"e_1_2_5_46_2","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos MA","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06230.x"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn554"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn526"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404682"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22681","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:25:44Z","timestamp":1700490344000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,23]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/pbc.22681"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22681","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,23]]}}}